• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Trevena Inc.

    3/31/25 4:01:19 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRVN alert in real time by email
    NT 10-K 1 tm2510912d1_nt10k.htm NT 10-K

     

    SEC File Number: 001-36193

    CUSIP Number: 89532E307

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check one):   x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D
        ¨ Form N-SAR ¨ Form N-CSR      
                 
        For Period Ended: December 31, 2024
        ¨ Transition Report on Form 10-K      
        ¨ Transition Report on Form 20-F      
        ¨ Transition Report on Form 11-K      
        ¨ Transition Report on Form 10-Q      
        ¨ Transition Report on Form N-SAR      
        For the Transition Period Ended:  

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I — REGISTRANT INFORMATION

     

    Trevena, Inc.

     

    Full Name of Registrant

     

     

    Former Name if Applicable

     

    2870 Peachtree Road, Suite 502

     

    Address of Principal Executive Office (Street and Number)

     

    Atlanta, GA 30305

     

    City, State and Zip Code

     

     

     

     

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      (a) The reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;
    x (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III — NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Trevena, Inc. (the “Company”) is filing this Notification of Late Filing on Form 12b-25 with respect to its Annual Report on Form 10-K for the year ended December 31, 2024 (the “Form 10-K”).

     

    The Form 10-K could not be filed within the prescribed time period without unreasonable effort or expense because the Company requires additional time and effort to prepare the Company’s 2024 financial statement, including completing its closing procedures and preparing the associated disclosure items. As a result, the Company is still in the process of compiling required information to complete the Form 10-K. The Company is diligently working to file the Form 10-K as soon as reasonably practicable on or before the fifteenth calendar day following the prescribed due date for the Form 10-K.

     

    PART IV — OTHER INFORMATION

     

    (1)Name and telephone number of person to contact in regard to this notification

     

    Carrie L. Bourdow   (610)   354-8840
    (Name)   (Area Code)   (Telephone Number)

     

    (2)Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

     

    x Yes ¨ No

     

    (3)Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

    ¨ Yes x No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    Forward Looking Statements

     

    This Form 12b-25 contains forward-looking statements within the meaning Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, the Company’s expectations as to the filing of the Annual Report. These forward-looking statements involve risks and uncertainties, and actual results could vary materially from these forward-looking statements. Factors that may cause future results to differ materially from management’s current expectations include the risk that the completion and filing of the Annual Report will take longer than expected, and the risk that the Company will be unable to file the Annual Report within the extension period of fifteen (15) calendar days provided under Rule 12b-25 of the Exchange Act. The Company disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise, except as required by law.

     

     

     

    Trevena, Inc.
    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: March 31, 2025 By: /s/ Carrie L. Bourdow
        Carrie L. Bourdow, Acting Chief Executive Officer

     

    ATTENTION

     

    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     

     

    Get the next $TRVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRVN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TRVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Sutton Katrine claimed ownership of 942 shares (SEC Form 3)

      3 - TREVENA INC (0001429560) (Issuer)

      12/6/24 4:39:03 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acting CMO Demitrack Mark covered exercise/tax liability with 885 shares, decreasing direct ownership by 7% to 11,363 units (SEC Form 4)

      4 - TREVENA INC (0001429560) (Issuer)

      10/10/24 5:08:47 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acting COO and CFO Shin Barry covered exercise/tax liability with 806 shares, decreasing direct ownership by 7% to 11,543 units (SEC Form 4)

      4 - TREVENA INC (0001429560) (Issuer)

      10/10/24 5:07:55 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVN
    Financials

    Live finance-specific insights

    See more
    • Trevena Reports Third Quarter 2023 Results and Provides Business Update

      Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement Company reported favorable safety and tolerability data from TRV045 POC studies Three abstracts for OLINVYK presented at American Society of Anesthesiologists (ASA) Conference $15 million tranche from ex-US royalty-based financing agreement received in September Company to host conference call today, November 14, 2023 at 8:00 a.m. ET CHESTERBROOK, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for pat

      11/14/23 7:00:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023

      CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the third quarter ended September 30, 2023, prior to the market open on Tuesday, November 14, 2023. The Company will host a conference call and webcast with the investment community at 8:00 a.m. ET that same day, featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Mark Demitrack, M.D., SVP and Chief Medical Officer, and Barry Shin, SVP and Chief Financial Office

      11/9/23 7:00:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update

      $15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena's partner in China New OLINVYK respiratory data from VOLITION ~200 patient real-world outcomes study, using continuous respiratory monitoring, expected 3Q 2023 Three OLINVYK abstracts accepted for presentation at upcoming American Society of Anesthesiologists Meeting in 4Q 2023 Company to participate in upcoming HC Wainwright conference (September 11-13) Company to Hold Conference Call on Wednesday, September 6 at 8 a.m. Eastern Time to discuss TRV045 Proof-of-Concept Data CHESTERBROOK, Pa., Sept. 06, 2023 (GLOBE NEWSWI

      9/6/23 7:01:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVN
    SEC Filings

    See more
    • Trevena Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - TREVENA INC (0001429560) (Filer)

      5/15/25 8:09:22 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Trevena Inc.

      25-NSE - TREVENA INC (0001429560) (Subject)

      4/8/25 9:20:54 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-K filed by Trevena Inc.

      NT 10-K - TREVENA INC (0001429560) (Filer)

      3/31/25 4:01:19 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Trevena Inc.

      SC 13G/A - TREVENA INC (0001429560) (Subject)

      11/14/24 4:43:11 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Trevena Inc.

      SC 13G - TREVENA INC (0001429560) (Subject)

      9/19/24 4:09:55 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Trevena Inc. (Amendment)

      SC 13G/A - TREVENA INC (0001429560) (Subject)

      2/14/24 2:34:30 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Trevena Reports Third Quarter 2024 Results and Provides Business Update

      CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended September 30, 2024 and provided an overview of its recent operational updates. Third Quarter 2024 and Recent Corporate Updates $2 million Non-Dilutive Financing Tranche. In July 2024, the Company announced receipt of a non-dilutive, $2 million tranche in connection with an amendment (the "Amendment") to its existing ex-US royalty financing with R-Bridge Healthcare Fund ("R-Bridge"). The Compa

      11/7/24 7:01:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevena Announces Receipt of Nasdaq Delisting Notification

      CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that on October 4, 2024 the Company received notice that the Nasdaq Hearings Panel (the "Panel") had determined to delist the Company's common stock from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with the minimum stockholder's equity requirement under Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard Rule"). As previously disclosed, the Panel had provided the Company until October 2, 2024, to regain comp

      10/4/24 4:05:00 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevena Announces Reverse Stock Split

      CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the "Amendment") to effect a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective at 12:01 a.m. ET on Tuesday, August 13, 2024. Trevena's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "TRVN" and will begin trading on a split-adjusted basis when the market opens on Tu

      8/8/24 4:05:00 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TRVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Oppenheimer initiated coverage on Trevena

      Oppenheimer initiated coverage of Trevena with a rating of Market Perform

      3/15/21 7:02:03 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Trevana

      Oppenheimer initiated coverage of Trevana with a rating of Perform

      3/15/21 6:50:29 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors

      CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Corrigan, M.D. has been appointed to the Company's Board of Directors, effective July 18 2023. "We are pleased to welcome Mark to Trevena's Board of Directors," said Carrie Bourdow, Trevena's President and CEO. "Mark has over 30 years of experience in the life sciences industry and broad neuroscience expertise. He will be an invaluable member of the Board and guide to the management team as we continue to execute on our corporate

      7/20/23 7:00:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Imvax Appoints John M. Limongelli as Chief Legal Officer

      Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of John M. Limongelli as the Company's Chief Legal Officer effective September 16, 2021. "John's breadth of experience in the biopharma industry, his deep technical acumen, and his expertise at helping build strong corporate practices will be of invaluable benefit to our leadership team," said John Furey, Chief Executive Officer. "As we work to expand our platform to address a variety of solid tumors, John's expertise will be an essential part of the development of these assets." Mr. Limongelli is an accomplished executive officer and lawyer with near

      9/16/21 8:00:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care